452 related articles for article (PubMed ID: 15548480)
21. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
22. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
[TBL] [Abstract][Full Text] [Related]
23. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
25. Levodopa in Mucuna pruriens and its degradation.
Pulikkalpura H; Kurup R; Mathew PJ; Baby S
Sci Rep; 2015 Jun; 5():11078. PubMed ID: 26058043
[TBL] [Abstract][Full Text] [Related]
26. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
Djaldetti R; Rosmarin V; Ziv I; Melamed E
Clin Neuropharmacol; 2001; 24(2):95-8. PubMed ID: 11307044
[TBL] [Abstract][Full Text] [Related]
27. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Luginger E; Wenning GK; Bösch S; Poewe W
Mov Disord; 2000 Sep; 15(5):873-8. PubMed ID: 11009193
[TBL] [Abstract][Full Text] [Related]
28. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
[TBL] [Abstract][Full Text] [Related]
29. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Papathanou M; van der Laan R; Jenner P; Rose S; McCreary AC
Mov Disord; 2013 Jul; 28(8):1072-9. PubMed ID: 23125107
[TBL] [Abstract][Full Text] [Related]
30. Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?
Fothergill-Misbah N; Maroo H; Cham M; Pezzoli G; Walker R; Cilia R
Parkinsonism Relat Disord; 2020 Apr; 73():3-7. PubMed ID: 32179240
[TBL] [Abstract][Full Text] [Related]
31. Management of Parkinson's disease in Ayurveda: Medicinal plants and adjuvant measures.
Pathak-Gandhi N; Vaidya AD
J Ethnopharmacol; 2017 Feb; 197():46-51. PubMed ID: 27544001
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Manyam BV; Dhanasekaran M; Hare TA
Phytother Res; 2004 Sep; 18(9):706-12. PubMed ID: 15478206
[TBL] [Abstract][Full Text] [Related]
33. Estimation of L-dopa from Mucuna pruriens LINN and formulations containing M. pruriens by HPTLC method.
Modi KP; Patel NM; Goyal RK
Chem Pharm Bull (Tokyo); 2008 Mar; 56(3):357-9. PubMed ID: 18310948
[TBL] [Abstract][Full Text] [Related]
34. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
36. Japanese Mucuna pruriens (Hasshou beans) Showed Fast-acting and Long-lasting Effects in Parkinson's Disease.
Sakata M; Miyamoto K; Koh J; Nagashima Y; Kondo T; Ito H
Intern Med; 2024 Mar; ():. PubMed ID: 38462520
[TBL] [Abstract][Full Text] [Related]
37. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
38. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
39. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study.
Carroll CB; Bain PG; Teare L; Liu X; Joint C; Wroath C; Parkin SG; Fox P; Wright D; Hobart J; Zajicek JP
Neurology; 2004 Oct; 63(7):1245-50. PubMed ID: 15477546
[TBL] [Abstract][Full Text] [Related]
40. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
